Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer by Montgomery, Bruce et al.
Montgomery et al. BMC Cancer 2010, 10:244
http://www.biomedcentral.com/1471-2407/10/244
Open Access RESEARCH ARTICLE
© 2010 Montgomery et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Research article Estradiol suppresses tissue androgens and prostate 
cancer growth in castration resistant prostate 
cancer
Bruce Montgomery*1, Peter S Nelson4, Robert Vessella2, Tom Kalhorn3, David Hess5 and Eva Corey 2
Abstract
Background: Estrogens suppress tumor growth in prostate cancer which progresses despite anorchid serum 
androgen levels, termed castration resistant prostate cancers (CRPC), although the mechanisms are unclear. We 
hypothesize that estrogen inhibits CRPC in anorchid animals by suppressing tumoral androgens, an effect 
independent of the estrogen receptor.
Methods: The human CRPC xenograft LuCaP 35V was implanted into orchiectomized male SCID mice and established 
tumors were treated with placebo, 17β-estradiol or 17β-estradiol and estrogen receptor antagonist ICI 182,780. Effects 
of 17β-estradiol on tumor growth were evaluated and tissue testosterone (T) and dihydrotestosterone (DHT) evaluated 
by mass spectrometry.
Results: Treatment of LuCaP 35V with 17β-estradiol slowed tumor growth compared to controls (tumor volume at day 
21: 785 ± 81 mm3 vs. 1195 ± 84 mm3, p = 0.002). Survival was also significantly improved in animals treated with 17β-
estradiol (p = 0.03). The addition of the estrogen receptor antagonist ICI 182,780 did not significantly change survival or 
growth. 17β-estradiol in the presence and absence of ICI 182,780 suppressed tumor testosterone (T) and 
dihydrotestosterone (DHT) as assayed by mass spectrometry. Tissue androgens in placebo treated LuCaP 35V 
xenografts were; T = 0.71 ± 0.28 pg/mg and DHT = 1.73 ± 0.36 pg/mg. In 17β-estradiol treated LuCaP35V xenografts 
the tissue androgens were, T = 0.20 ± 0.10 pg/mg and DHT = 0.15 ± 0.15 pg/mg, (p < 0.001 vs. controls). Levels of T and 
DHT in control liver tissue were < 0.2 pg/mg.
Conclusions: CRPC in anorchid animals maintains tumoral androgen levels despite castration. 17β-estradiol 
significantly suppressed tumor T and DHT and inhibits growth of CRPC in an estrogen receptor independent manner. 
The ability to manipulate tumoral androgens will be critical in the development and testing of agents targeting CRPC 
through tissue steroidogenesis.
Background
The Nobel prize winning work of Huggins and Hodges
described the use of estrogens and orchiectomy in the
treatment of prostate cancer [1,2]. With the development
of LHRH agonists, and the recognition that oral estrogens
carried a significant risk of vascular complications,
LHRH agonists supplanted estrogens as a primary treat-
ment for advanced disease [3]. The use of diethylstilbe-
strol, and more recently transdermal estradiol, [4,5]
remains relevant because estrogens can induce PSA
response rates as high as 45% in selected patients with
early "androgen-independent" or castration resistant
prostate cancer (CRPC) [6]. Estrogens ameliorate toxici-
ties associated with androgen deprivation by maintaining
bone mineral density, suppressing hot flushes and
improving both cognitive function and lipids in men with
anorchid testosterone levels [7-9].
The relatively high response rate of castration resistant
prostate cancer to secondary manipulations with estro-
gens and ketoconazole has been ascribed to suppression
of adrenal androgen production [10,11]. Other investiga-
tors have suggested that estrogens directly inhibit growth
of prostate cancer when administered in vitro in the
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absence of circulating hormones [12]. We have previously
shown that 17β-estradiol suppressed CRPC growth and
delayed mortality in multiple castration resistant xeno-
graft models in vivo [13]. In these castrate animals, estro-
gen suppressed tumor growth despite the lack of
circulating testosterone, dehydroepiandrosterone
(DHEA) and androstenedione synthesis, a feature result-
ing from a lack of CYP17 in murine adrenal glands [14].
The estradiol inhibition of these human prostate cancer
xenografts in castrated mice must therefore be indepen-
dent of both testicular and adrenal androgens. Potential
mechanisms of tumor suppression include receptor
dependent inhibition through estrogen receptor β,
[15,16]or receptor independent mechanisms such as
induction of immune surveillance, or metabolism of 17β-
estradiol to cytotoxic estrogens such as 2-methoxyestra-
diol [17]. We have demonstrated that metastases from
men with progressive CRPC contain testosterone levels
significantly higher than those in prostate cancer tissue
from eugonadal men. Moreover, elevated tumoral andro-
gens were associated with increased tumor transcripts
encoding enzymes involved in the synthesis of androgens
[18]. These studies suggested that prostate cancer can
maintain intratumoral androgens to aid in tumor pro-
gression in CRPC. In the current study we hypothesize
that 17β-estradiol might inhibit CRPC growth in
anorchid hosts and suppress tumoral androgens by com-
petitively inhibiting steroidogenesis from cholesterol, and
reduce available tumoral androgens that drive growth
[19-22]
In the current study we analyzed the effect of estradiol
on tissue androgen levels in the castration resistant
LuCaP 35V human prostate xenograft, demonstrating
suppression of tumoral androgens. Tumor suppression in
this model by estradiol was independent of the estrogen
receptor, suggesting that competitive inhibition of andro-
gen metabolism within tumor tissue is another potential
mechanism by which estradiol and other estrogens
inhibit prostate cancer growth.
Methods
Xenograft studies
All procedures were performed in compliance with the
University of Washington Institutional Animal Care and
Use Committee and NIH guidelines. Four- to 6-week-old
male SCID mice (Fox Chase SCID mice, Charles River,
Wilmington, MA) were used. The animals were orchiec-
tomized at 8 weeks of age, and all animals were implanted
with tumors at least 2 weeks after surgery. Tumor bits
(20-30 mm3) of human castration resistant prostate
tumor xenograft LuCaP 35V were implanted subcutane-
ously. LuCaP 35 originated from a lymph node prostate
cancer metastasis from a patient with androgen resistant
prostate cancer. Both the castration sensitive (CS) LuCaP
35 and isogenic, castration resistant LuCaP 35V express
PSA and a wild-type androgen receptor [23]. Tumor
growth was monitored by tumor measurements twice a
week using calipers, and tumor volume was calculated as
0.5236 × LxHxW. When tumors reached 150 to 400 mm3,
the animals were randomized into three groups. Group 1
(n = 10), the control group, were implanted with subcuta-
neous placebo pellets (Innovative Research of America,
Sarasota, FL). Group 2 (n = 10): animals were supple-
mented with 17β-estradiol by subcutaneous implantation
of slow-release Trocar pellets (90-day release, 0.36 mg;
Innovative Research of America). Group 3 (n = 10): ani-
mals were implanted with 17β-estradiol pellets and the
estrogen receptor antagonist ICI 182,780 was injected
once a week (5 mg, subcutaneous injection) [24]. Control
tissue for androgens was assayed from non-xenograft tis-
sue from the same animals as well as from isogenic cas-
tration sensitive LuCaP 35 growing in eugonadal male
mice. Effects of the treatments were monitored by
biweekly measurements of tumor volume. Animals were
sacrificed when tumors exceeded 1000 mm3 or when the
animals became compromised. Tumors were snap frozen
in liquid nitrogen and stored at -80°C. Efficacy of the dif-
ferent treatment methods was assessed as average tumor
volumes per group after 3 weeks of treatment. Growth
delay was measured as the time from the start of treat-
ment to the time for tumors to reach a volume of 1000
mm3 [25]. All procedures were performed in compliance
with the University of Washington Institutional Animal
Care and Use Committee
Statistical Analyses
The significance of differences in survival rate was tested
using the log-rank statistic. Statistical significance
between androgens in tissues of control and treated ani-
mals, differences in tumor volume at fixed intervals, and
time to tumor volume of 1000 mm3 were assayed using
Student's t test; 95% confidence interval, and P ≤ 0.05 was
considered significant.
Steroid measurements
Androgen levels were determined by mass spectrometry
(MS) using methods we have recently described [26]. In
brief, frozen tissue samples were individually thawed,
weighed, and homogenized in PBS. The homogenates
were extracted with 8 ml of diethyl ether and the organic
phase decanted after freezing the aqueous phase in a dry
ice/ethanol bath. The organic phase was dried and con-
centrated with 2 × 0.5 ml ether washes under a stream of
purified air. Each individual concentrated extract was dis-
solved in 1.0 ml redistilled ethanol and stored at -20°C
until MS analysis. Samples were spiked with internal
standards: 50 pg of deuterated (D3)-DHT and D3-testos-
terone, vortexed briefly, and evaporated to dryness. TheMontgomery et al. BMC Cancer 2010, 10:244
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residue was then reconstituted in 0.5 mL of water prior to
extraction with methylene chloride. The organic phase
was removed under nitrogen and the sample was dis-
solved in 0.1 M hydroxylamine hydrochloride in 50%
MeOH/water, vortexed, and heated at 60° for 1 hour.
Standards for DHT and testosterone were prepared in
parallel. The resulting oximes were analyzed by LC-MS-
MS using a Waters Aquity HPLC and Premier XE mass
spectrometer (Milford, MA). Ions monitored were 350 >
309 and 347 > 306 for DHT-IS and DHT respectively, and
307 > 124 and 304 > 124 for testosterone-IS and testoster-
one respectively. This procedure resulted in a lower limit
of quantitation of 100 and 500 attoMoles on column for
testosterone and DHT respectively. Intra-assay coeffi-
cients of variation generated using human serum for
high, mid and low-range samples were 3.5, 3.1 and 3.8%
for testosterone and 6.3, 4.3 and 15.8% for DHT respec-
tively. Data for tissue androgens was derived from 2-5
tumor samples per data point. Estradiol levels were per-
formed on mouse serum collected at the time of sacrifice
and assayed by ELISA (IBL, Hamburg).
Results
Effect of estradiol on tumor growth in orchiectomized mice
Previous studies have shown that 17β-estradiol sup-
presses tumor growth in ovariectomized mice bearing
prostate cancer xenografts LuCaP 35, LuCaP 49, LuCaP
58, LuCaP 73, and LNCaP [13]. These studies demon-
strated that estradiol suppression of tumor growth was
independent of effects on testicular androgens. We inves-
tigated whether estradiol suppression of castration resis-
t a n t  p r o s t a t e  c a n c e r  g r o w t h  i s  d e p e n d e n t  o n  e s t r o g e n
receptor and independent of adrenal androgens. To
address this question we examined the effect of 17β-
estradiol on the castration resistant human prostate can-
cer xenograft LuCaP 35V in orchiectomized male mice in
the presence and absence of the estrogen receptor antag-
onist ICI 182,780 (Faslodex). As previously discussed,
adult male mice do not synthesize DHEA or androstene-
dione because the enzyme CYP17 is not expressed in the
adult rodent adrenal gland [14]. Serum estradiol was col-
lected from xenograft bearing animals at the time of sac-
rifice. Estradiol levels from control animals were 79.7 ±
67.9 pg/mL (mean ± standard deviation), levels from ani-
mals treated with 17β-estradiol alone were 636.9 ± 321.6,
and animals treated with the combination of ICI 182,780
and 17β-Estradiol levels had had levels of 731.6 ± 508.5
pg/mL. Differences between the estradiol treated groups
were not significant (p > 0.1). As shown on Fig. 1, 17β-
estradiol prolongs survival of animals compared to con-
trols (median survival 21 vs. 24 days, p = 0.03) and the
administration of ICI 182,780 did not significantly change
the effect of estradiol on survival (p = 0.14).
The mean tumor volumes at week 3 of treatment are
shown in Table 1., The average tumor volume in the con-
trol group was significantly higher than in the 17β-estra-
diol treated group (Table 1, p = 0.02). The differences
between 17β-estradiol and estradiol with ICI 182,780
were not statistically significant, though tumor volumes
appeared slightly lower in animals treated with estradiol
and ICI 182,780. Another way of quantitating effects on
Table 1: Tumor growth in response to 17β-estradiol and ICI 182,780
Groups Tumor volume on Day 21 (mm3) (SE) Days to 1000 mm3 (SE)
Control 1194.9 (83.9) 19.4 (1.2)
Estradiol 784.7 (81.1) * 25.7 (3.4) †,
Estradiol/ICI 675.2 (77.2) ** 33.4 (4.4) ††
* p = 0.002 vs. control †, p = 0.05 vs. control
** p = 0.001 vs. control. †† p = 0.003 vs. control
Figure 1 Effect of 17β-estradiol or 17β-estradiol combined with 
ICI 182,780 on human CRPC xenograft growth in SCID mice. Cas-
trated SCID male mice were implanted with LuCaP 35V castration re-
sistant cells and when tumors reached 150-400 mm3, treated with 
placebo pellets (n = 10): 17β-estradiol by subcutaneous pellets (n = 
10); or 17β-estradiol pellets and ICI 182,780 (5 mg/kg SC once per 
week) as detailed in Materials and Methods. Data shown are Kaplan-
Meier estimates of survival for tumor bearing animals treated with in-
dicated agents.
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tumor growth is a comparison of the median time to
reach a specified tumor volume [25]. This analysis shows
that the time to a tumor volume of 1000 mm3 (the pre-
specified point at which animals would be sacrificed) was
also significantly different among the control group and
the other two groups and reflects more rapid tumor
growth (Table 1). Overall, 17β-estradiol extended the
time to sacrifice by a median of 6 days (p = 0.002). The
difference between the 17β-estradiol and estradiol/ICI
182,780 groups was not statistically different (p = 0.34).
Although the use of ICI 182,780, did not result in differ-
ences in tumor growth which were statistically signifi-
cant, there was a trend toward greater effect for the
combination of estradiol with ICI 182,780. This might
reflect additional efficacy of blocking estrogen receptor,
or might reflect the higher serum estradiol levels in ani-
mals treated with estradiol and ICI 182,780. ICI 182,780
is metabolized via CYP3A4, which also metabolizes
estradiol, suggesting one potential mechanism by which
ICI 182,780 treatment might modulate estradiol levels
The lack of a statistically significant difference in tumor
growth with use of the estrogen receptor antagonist
strongly suggests that tumor inhibition is independent of
the estrogen receptor as well as androgens derived from
testicular and adrenal sources.
Estradiol effects on tumoral testosterone and DHT levels
We next sought to determine how estradiol might be
mediating an anti-tumor effect independent of circulat-
ing androgens, and independent of estrogen receptor. We
have reported that metastatic prostate cancer from
androgen deprived individuals contains supraphysiologic
levels of tissue testosterone in the presence of increased
transcripts encoding enzymes of steroidogenesis [18].
Estradiol can suppress the expression and enzyme activ-
ity of critical proteins in the steroidogenesis pathway.
Sensitive components of the pathway include Steroido-
genic acute regulatory protein (StAR), CYP17 and 3β-
hydroxysteroid dehydrogenase [20-22]. To evaluate
LuCaP 35V xenograft tissue androgens in the presence
and absence of estradiol, we assayed tumoral testosterone
and DHT by LC-MS/MS. Our results show that despite
castration, the LuCaP 35V xenograft maintains tissue lev-
els of androgens which approximate those found in tumor
tissue in eugonadal men and are of a magnitude equiva-
lent to those in the castration sensitive, isogenic line
LuCaP 35 grown in eugonadal male mice. With estradiol
exposure tumoral levels of androgens decline signifi-
cantly (Fig. 2). Tissue testosterone levels in placebo
treated LuCaP 35V xenografts were 0.71 ± 0.28 pg/mg
and DHT concentrations were 1.73 ± 0.36 pg/mg. In
estradiol treated LuCaPV35 the tissue testosterone con-
centrations were 0.20 ± 0.10 pg/mg and DHT levels were
0.15 ± 0.15 pg/mg, (p < 0.001 compared to controls). Lev-
els in the tumors from animals treated with both estradiol
and ICI 182,780 were not statistically different from those
in tumors treated with estradiol alone. Liver from treated
animals was used as control tissue as it lacks steroido-
genic enzymes and does not contain elevated androgens
in castrate animals [18]. Levels of T and DHT in control
liver tissue from placebo and estradiol treated animals,
were less than 0.2 pg/mg. Testosterone in castration sen-
sitive tumors in intact mice was higher , and DHT was
lower, than in the castrate animals. Although estradiol
administration suppressed tissue androgens significantly,
in association with a decrease in tumor growth, tumoral
androgen levels did not reach the very low levels seen in
control tissues. These residual androgens are still in the
range expected to continue to activate the receptor, albeit
significantly lower than those in tumors which were not
treated with estradiol. These findings likely explain the
incomplete tumor suppression seen with estradiol ther-
apy. In summary, estradiol significantly suppresses both
tumor growth and tumoral androgens in the absence of
circulating testicular or adrenal androgens.
Discussion
Estrogens have long played a role in the treatment of
advanced prostate cancer, however the mechanism of
efficacy in men who have already developed resistance to
androgen-deprivation therapies has been uncertain.
Estrogens induce feedback inhibition of LH secretion in
patients with an intact hypothalamic-pituitary axis,
resulting in decreased testosterone production. An early
VA Cooperative Urology Group study compared the
estrogen diethylstilbestrol (DES) to orchiectomy, and
demonstrated that DES provided better cancer specific
survival than orchiectomy, but cardiovascular mortality
offset the improved disease control [27]. This study raised
the possibility that estrogens might inhibit cancer growth
independently of simple suppression of testicular andro-
gen production. In support of that idea, our group has
previously shown that estradiol inhibits multiple castra-
tion resistant human prostate cancer xenografts in cas-
trated animals, however the mechanism remained
ambiguous. This study was carried out to determine if
estrogen inhibition of prostate cancer xenograft growth
was estrogen receptor dependent, and whether estrogen
might be mediating its effect by suppressing tissue andro-
gens which could support tumor survival and prolifera-
tion. The data presented here strongly suggest that
estradiol inhibition of tumor growth in this setting is
estrogen receptor independent, as ICI 182,780 blocks
both ERα and β signaling, yet did not abrogate estradiol
mediated tumor suppression. In addition, estradiol
clearly suppressed tumor androgen levels, an effect for
which there is no plausible mechanism in castrated ani-
mals lacking functional adrenal CYP17. The xenograftsMontgomery et al. BMC Cancer 2010, 10:244
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used in these studies express wild type AR, not mutant
AR and are therefore not expected to bind estradiol. It
was first reported by Geller, and subsequently by others
that prostate tissue in androgen deprived individuals
maintains levels of DHT and testosterone which are
between 20 and 50% those found in tissue from eugo-
nadal men [28-32]. Maintenance of these tissue levels
despite anorchid serum levels might occur either through
sequestration of androgens, or by metabolism or synthe-
sis of androgens from earlier precursors. The idea of tis-
sue "intracrine" synthesis of androgen was proposed
initially by Labrie et al [33]. This mechanism would
incorporate the ability of estrogen to suppress tumor
growth independent of gonadal or adrenal androgens.
This report is the first to clearly demonstrate that pros-
tate cancer xenografts maintain tissue androgens inde-
pendent of endocrine function, in castrate hosts. It is also
the first report that demonstrates that estradiol inhibition
of tumor growth in this setting is not ER dependent and
that estradiol effectively suppresses tumoral androgen
levels, a result which might explain an ER independent
mechanism of blocking castration resistant tumor
growth. This data supports the concept that tissue andro-
gens are not necessarily dependent on endocrine organ
function. The importance of residual androgens is uncer-
tain unless these tissue levels can be further suppressed
to slow tumor growth, an effect which has been demon-
strated in this study. Although not defined in these exper-
iments, the most parsimonious explanation of the ability
of estrogen to effect this change would be through its
ability as a steroidal hormone to competitively inhibit the
relatively promiscuous enzymes of steroidogenesis which
might mediate tissue metabolism [19-22]. Multiple ste-
roidal hormones are capable of interacting with steroid
transporters and competitively inhibiting metabolism of
other substrates, in any tissue which contains these
enzymes.
Extrapolation of the results of xenograft studies to the
biology of metastatic prostate cancer in man remains
speculative. In patients with advanced prostate cancer,
suppression of androgen production by orchiectomy or
LHRH agonist administration has a transient, although
significant impact on prostate cancer growth. Remark-
ably, despite the immediate clinical benefits of androgen
deprivation, the tissue effects of suppressing serum
androgen levels are much more modest. Our group has
reported that benign prostate tissue as well as prostate
cancers maintain physiologic levels of both testosterone
Figure 2 Androgen levels in LuCaP prostate cancer human prostate cancer xenografts grown in castrate and intact SCID mice. Testosterone 
and DHT levels were measured by mass spectrometry in castration sensitive (CS) and castration resistant variants of the LuCaP 35 xenograft. The cas-
tration resistant tumors were treated with agents as indicated (Fig. 1 and Materials and Methods). Androgen levels were also evaluated in liver tissue 
obtained from each set of treated castrate animals. Data represent three tissue samples per data point; bars, SE.
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and DHT despite effective suppression of serum andro-
gens [31]. The ability of prostate tissue to maintain local
hormone levels is reflected in the minimal change in the
expression of androgen regulated gene expression in men
with anorchid serum androgens [31]. These findings may
explain the observation by Agus and colleagues that
androgen deprivation in prostate cancer xenograft mod-
els demonstrated only transient cell cycle arrest, with lit-
tle evidence of apoptosis, followed by relatively rapid
progression [34]. The persistence of tissue androgens
despite anorchid serum levels would be anticipated to
continue to support prostate cancer cell survival, and
growth over time.
Estrogens, including, ethinyl estradiol, DES, and trans-
dermal estradiol remain an option for patients with both
androgen dependent and castration resistant prostate
cancer [4-6,35,36]. The current study provides evidence
that a component of estrogen activity occurs though
reductions of tissue androgen levels even when serum
androgens are completely suppressed by castration. The
effect is independent of estrogen receptor, and suggests
that further investigation of how tumoral androgens play
a role in progressive CRPC are warranted. Studies to elu-
cidate the mechanism(s) by which tissue androgens are
maintained will be critical for understanding the impor-
tance of this phenomenon. This becomes more important
as agents become available which can more effectively
modulate interactions between intracrine ligands and the
AR, including high affinity AR antagonists and agents
which interfere with enzymes of steroidogenesis [37,38]
Conclusions
The current study demonstrates that estradiol slows
tumor progression of CRPC xenografts grown in orchiec-
tomized mice. The inhibition of tumor progression is
associated with the ability of estradiol to inhibit intratu-
moral androgen levels, which at baseline are unexpect-
edly higher than would be expected in the context of no
serum testosterone, and a lack of serum DHEA. The use
of estradiol receptor antagonist did not block estradiol
inhibition of tumor growth, nor did it change the sup-
pression of tumor androgens, suggesting that both effects
are independent of estrogen receptor. This study suggests
that the known ability of secondary hormonal manipula-
tions to suppress CRPC growth is related to inhibition of
tumoral androgens, and in this specific study is indepen-
dent of adrenal DHEA production. This has implications
for the design of future therapies targeting different arms
of steroidogenesis in prostate cancer as more effective
treatment.
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